Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors



Status:Recruiting
Conditions:Brain Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 21
Updated:2/24/2019
Start Date:July 24, 2017
End Date:June 3, 2020

Use our guide to learn which trials are right for you!

A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan

This phase I trial studies the side effects and best dose of nanoparticle albumin-bound
rapamycin when given together with temozolomide and irinotecan hydrochloride in treating
pediatric patients with solid tumors that have come back after a period of time during which
the tumor could not be detected or has not responded to treatment. Nanoparticle albumin-bound
rapamycin may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Drugs used in chemotherapy, such as temozolomide and irinotecan hydrochloride, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving nanoparticle albumin-bound
rapamycin, temozolomide, and irinotecan hydrochloride may work better in treating pediatric
patients with solid tumors.

PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of
nanoparticle albumin-bound rapamycin (ABI-009) administered as an intravenous infusion over
30 minutes on days 1 and 8 of a 21-day cycle, in combination with temozolomide and irinotecan
hydrochloride (irinotecan) (administered on days 1-5) in pediatric patients with recurrent or
refractory solid tumors, including central nervous system (CNS) tumors.

II. To define and describe the toxicities of single-agent ABI-009 administered as an
intravenous infusion over 30 minutes on days 1 and 8 of a 21-day cycle in pediatric patients
with recurrent or refractory solid tumors, including CNS tumors.

III. To define and describe the toxicities of ABI-009 administered as an intravenous infusion
over 30 minutes on days 1 and 8 of a 21-day cycle in combination with temozolomide and
irinotecan (administered on days 1-5) in pediatric patients with recurrent or refractory
solid tumors, including CNS tumors.

IV. To characterize the pharmacokinetics of ABI-009 in pediatric patients with recurrent or
refractory solid tumors, including CNS tumors.

SECONDARY OBJECTIVES:

I. To preliminarily define the antitumor activity of ABI-009 in combination with temozolomide
and irinotecan within the confines of a phase 1 study.

TERTIARY OBJECTIVES:

I. To assess the biologic activity of ABI-009 by examining S6K1 and 4E-BP1 expression status
in archival tumor tissue from solid tumor pediatric patients using immunohistochemistry.

OUTLINE: This is a dose-escalation study of nanoparticle albumin-bound rapamycin.

Patients receive nanoparticle albumin-bound rapamycin intravenously (IV) over 30 minutes on
days 1 and 8 beginning on course 1. Patients also receive temozolomide orally (PO) and
irinotecan hydrochloride PO on days 1-5 beginning on course 2. Treatment repeats every 21
days for up to 35 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

Inclusion Criteria:

- Patients must have a body surface area (BSA) of >= 0.2 m^2 at the time of study
enrollment

- Patients with recurrent or refractory solid tumors, including CNS tumors, are
eligible; patients must have had histologic verification of malignancy at original
diagnosis or relapse except in patients with intrinsic brain stem tumors, optic
pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid
(CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic
gonadotropin (HCG)

- Patients must have either measurable or evaluable disease

- Patient?s current disease state must be one for which there is no known curative
therapy

- Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16
years of age

- Note: Neurologic deficits in patients with CNS tumors must have been relatively
stable for at least 7 days prior to study enrollment; patients who are unable to
walk because of paralysis, but who are up in a wheelchair, will be considered
ambulatory for the purpose of assessing the performance score

- Patients must have fully recovered from the acute toxic effects of all prior
anti-cancer therapy and must meet the following minimum duration from prior
anti-cancer directed therapy prior to enrollment; if after the required timeframe, the
numerical eligibility criteria are met, e.g. blood count criteria, the patient is
considered to have recovered adequately

- Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive; the
duration of this interval must be discussed with the study chair and the
study-assigned research coordinator prior to enrollment

- >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42
days if prior nitrosourea)

- Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced
platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of
agent; the duration of this interval must be discussed with the study chair and the
study-assigned research coordinator prior to enrollment

- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and
toxicity related to prior antibody therapy must be recovered to grade =< 1

- Corticosteroids: If used to modify immune adverse events related to prior therapy, >=
14 days must have elapsed since last dose of corticosteroid

- Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth
factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for agents that
have known adverse events occurring beyond 7 days after administration, this period
must be extended beyond the time during which adverse events are known to occur; the
duration of this interval must be discussed with the study chair and the
study-assigned research coordinator

- Interleukins, interferons and cytokines (other than hematopoietic growth factors): >=
21 days after the completion of interleukins, interferon or cytokines (other than
hematopoietic growth factors)

- Stem cell infusions (with or without total body irradiation [TBI]):

- Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell
infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days
after infusion, and no evidence of graft-versus-host disease (GVHD)

- Autologous stem cell infusion including boost infusion: >= 42 days

- Cellular therapy: >= 42 days after the completion of any type of cellular therapy
(e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)

- X ray (XRT)/external beam irradiation including protons: >= 14 days after local XRT;
>= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42
days if other substantial bone marrow (BM) radiation

- Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131 iodine
metaiodobenzylguanidine [131I-MIBG]): >= 42 days after systemically administered
radiopharmaceutical therapy

- Irinotecan, temozolomide and mammalian target of rapamycin (mTOR) inhibitor exposure:

- Patients who have received prior single agent therapy with irinotecan,
temozolomide, or an mTOR inhibitor, excluding ABI-009, are eligible

- Patients who have received prior therapy with ABI-009 are not eligible

- Patients who have previously received irinotecan and temozolomide in combination
without progressive disease while on therapy are eligible

- Patients who have previously received irinotecan and temozolomide in combination
and had significant toxicity with these two drugs are not eligible

- Patients who have received prior therapy with all three agents in combination
(i.e. irinotecan, temozolomide, and an mTOR inhibitor) are not eligible

- For patients with solid tumors without known bone marrow involvement:

- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3

- Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving
platelet transfusions for at least 7 days prior to enrollment)

- Hemoglobin >= 8.0 g/dl at baseline (may receive red blood cell [RBC]
transfusions)

- Patients with known bone marrow metastatic disease will be eligible for the study if
they meet the following criteria:

- Peripheral absolute neutrophil count (ANC) >= 750/mm^3

- Platelet count >= 50,000/mm^3 (may receive transfusions provided they are not
known to be refractory to red cell or platelet transfusions)

- Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC]
transfusions, provided they are not known to be refractory to RBC transfusions);
these patients will not be evaluable for hematologic toxicity; at least 5 of
every cohort of 6 patients must be evaluable for hematologic toxicity for the
dose-escalation part of the study; if dose-limiting hematologic toxicity is
observed, all subsequent patients enrolled must be evaluable for hematologic
toxicity

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

- Age: maximum serum creatinine (mg/dL)

- 1 to < 2 years: 0.6 (male and female)

- 2 to < 6 years: 0.8 (male and female)

- 6 to < 10 years: 1 (male and female)

- 10 to < 13 years: 1.2 (male and female)

- 13 to < 16 years: 1.5 (male), 1.4 (female)

- >= 16 years: 1.7 (male), 1.4 (female)

- Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for
age

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x
ULN = 135 U/L; for the purpose of this study, the ULN for SGPT is 45 U/L

- Serum albumin >= 2 g/dL

- Pulse oximetry > 94% on room air if there is clinical indication for determination
(e.g. dyspnea at rest)

- Patients with seizure disorder may be enrolled if on non-enzyme inducing
anticonvulsants and well controlled

- Nervous system disorders (National Cancer Institute Common Terminology Criteria for
Adverse Events [NCI CTCAE] version 5.0) resulting from prior therapy must be =< grade
2 with the exception of decreased tendon reflex (DTR); any grade of DTR is eligible

- Serum triglyceride level =< 300 mg/dL

- Serum total cholesterol level =< 300 mg/dL

- Random or fasting blood glucose =< the upper normal limits for age; if the initial
blood glucose is a random sample that is outside of the normal limits, then follow-up
fasting blood glucose can be obtained and must be =< the upper normal limits for age

- International normalized ratio (INR) =< 1.5

- Not currently receiving anticoagulation therapy

- All patients and/or their parents or legally authorized representatives must sign a
written informed consent; assent, when appropriate, will be obtained according to
institutional guidelines

- Tissue blocks or slides must be sent for all patients; if tissue blocks or slides are
unavailable, the study chair must be notified prior to enrollment

Exclusion Criteria:

- Pregnant or breast-feeding women will not be entered on this study; pregnancy tests
must be obtained in girls who are post-menarchal; males or females of reproductive
potential may not participate unless they have agreed to use an effective
contraceptive method both during and for 6 months after participation in this study;
abstinence is an acceptable method of contraception

- Patients receiving corticosteroids must have been on a stable or decreasing dose of
corticosteroid for at least 7 days prior to enrollment; if used to modify immune
adverse events related to prior therapy, >= 14 days must have elapsed since last dose
of corticosteroid

- Patients who are currently receiving another investigational drug are not eligible

- Patients who are currently receiving other anti-cancer agents are not eligible

- Patients who are receiving cyclosporine, tacrolimus or other agents to prevent
graft-versus-host disease post bone marrow transplant are not eligible for this trial

- Patients must not have received enzyme-inducing anticonvulsants for at least 7 days
prior to enrollment

- Patients who are currently receiving therapeutic anticoagulants (including aspirin,
low molecular weight heparin, and others) are not eligible

- Patients must not be receiving any strong CYP3A4 or P-glycoprotein (P-gp) inducers or
inhibitors within 7 days prior to enrollment; moderate inducers or inhibitors of
CYP3A4 and P-gp should also be avoided during ABI-009 treatment, if possible

- Patients with interstitial lung disease and/or pneumonitis are not eligible

- Patients with a history of allergic reactions attributed to compounds of similar
composition, including macrolide and ketolide antibiotics, temsirolimus/other mTOR
inhibitors, temozolomide or irinotecan are not eligible

- Patients with hypersensitivity to albumin are not eligible

- Patients who have had or are planning to have the following invasive procedures are
not eligible:

- Major surgical procedure, laparoscopic procedure, open biopsy or significant
traumatic injury within 28 days prior to enrollment

- Subcutaneous port placement or central line placement is not considered major
surgery; external central lines must be placed at least 3 days prior to
enrollment and subcutaneous ports must be placed at least 7 days prior to
enrollment

- Core biopsy within 7 days prior to enrollment

- Fine needle aspirate within 7 days prior to enrollment

- NOTE: For purposes of this study, bone marrow aspirate and biopsy are not
considered surgical procedures and therefore are permitted within 14 days prior
to start of protocol therapy

- Patients with current deep vein thrombosis or deep vein thrombosis within the past 6
months are not eligible

- Patients with a history of, or current grade 4 depression are not eligible

- Patients who have an uncontrolled infection are not eligible

- Patients who have received a prior solid organ transplantation are not eligible

- Patients who in the opinion of the investigator may not be able to comply with the
safety monitoring requirements of the study are not eligible
We found this trial at
21
sites
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Principal Investigator: AeRang Kim
Phone: 888-823-5923
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
(205) 638-9100
Principal Investigator: Gregory K. Friedman
Phone: 888-823-5923
Children's Hospital of Alabama Children
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: James I. Geller
Phone: 888-823-5923
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Leo Mascarenhas
Phone: 888-823-5923
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Wayne L. Furman
Phone: 888-823-5923
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Principal Investigator: Josephine H. Haduong
Phone: 888-823-5923
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Elizabeth Fox
Phone: 888-823-5923
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Jean M. Tersak
Phone: 888-823-5923
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
(877) 475-6688
Principal Investigator: Rajen Mody
Phone: 888-823-5923
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Jason R. Fangusaro
Phone: 888-823-5923
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Margaret E. Macy
Phone: 888-823-5923
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Steven G. DuBois
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60614
Principal Investigator: Stewart Goldman
Phone: 888-823-5923
?
mi
from
Chicago, IL
Click here to add this to my saved trials
5 Richland Medical Park Dr
Columbia, South Carolina 29203
(803) 434-7000
Principal Investigator: Stuart L. Cramer
Phone: 803-434-3680
Palmetto Health Richland Palmetto Health Richland, originally founded in 1892 as Columbia Hospital, has a...
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Jodi Muscal
Phone: 713-798-1354
?
mi
from
Houston, TX
Click here to add this to my saved trials
705 Riley Hospital Dr
Indianapolis, Indiana 46202
(317) 944-5000
Principal Investigator: James M. Croop
Phone: 800-248-1199
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Emily G. Greengard
Phone: 888-823-5923
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Alice Lee
Phone: 212-305-6361
?
mi
from
New York, NY
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Robert J. Hayashi
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94158
Principal Investigator: Kieuhoa T. Vo
Phone: 877-827-3222
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Julie R. Park
Phone: 888-823-5923
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials